Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (Jiuyuan Gene) announced the formal completion of its H-share full-circulation plan. On 14 May 2026, 136.30 million previously unlisted domestic shares were converted into H shares, with trading set to commence on the Hong Kong Stock Exchange at 9:00 a.m. on 15 May 2026.

Following the conversion, the company’s entire issued share capital of 245.40 million shares is now fully tradable as H shares. Prior to the move, H shares totaled 109.10 million, representing 44.5 % of the share base, while 136.30 million shares (55.5 %) remained unlisted. Post-conversion, Jiuyuan Gene’s H-share count has risen to 245.40 million, equivalent to 100 % of the company’s issued shares.

The milestone follows a series of regulatory approvals: shareholder endorsement on 22 December 2025, a filing notice from the China Securities Regulatory Commission on 2 April 2026, and listing approval from the Hong Kong Stock Exchange on 8 May 2026.

Management advises shareholders and potential investors to exercise caution when dealing in the company’s shares.